Chronic cannabis abuse raises nerve growth factor serum concentrations in drug-naive schizophrenic patients

Journal of Psychopharmacology

Volumn 17, Issue 4, 2003, Pages 439-445

  Jockers Scherübl, Maria C ^a   Matthies, Uta ^a   Danker Hopfe, Heidi ^a   Lang, Undine E ^a   Mahlberg, Richard ^a   Hellweg, Rainer ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Cannabis; Drug naive; Multiple substance abuse; Nerve growth factor; Neurodevelopment; Schizophrenia

Indexed keywords

CANNABIS; NERVE GROWTH FACTOR; NEUROTROPHIC FACTOR;

ADULT; ARTICLE; CANNABIS ADDICTION; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE DRUG ABUSE; NERVE CELL LESION; NEUROTOXICITY; ONSET AGE; PRIORITY JOURNAL; RISK FACTOR; SCHIZOPHRENIA;

ADOLESCENT; ADULT; CANNABIS; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; MARIJUANA ABUSE; MIDDLE AGED; NERVE GROWTH FACTOR; RISK FACTORS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; STREET DRUGS; SUBSTANCE-RELATED DISORDERS;

EID: 0346024160     PISSN: 02698811     EISSN: None     Source Type: Journal    
DOI: 10.1177/0269881103174007     Document Type: Article

References (55)

1. Aasley J, Storsaeter O, Nilsen G, Smevik O, Rinck P (1993) Minor structural brain changes in young drug abusers. Acta Neurol Scand 87: 210-214
2. Adams I B, Martin B R (1996) Cannabis: pharmacology and toxicology in animals and humans. Addiction 91: 1585-1614
3. Aloe L, Tuveri M A, Guerra G, Pinna L, Tirassa P, Micera A, Alleva E (1996) Changes in human plasma nerve growth factor level after chronic alcohol consumption and withdrawal. Alcohol Clin Exp Res 20: 462-465
4. Aloe L, Iannitelli A, Bersani G, Alleva E, Angelucci F, Maselli P, Manni L (1997) Haloperidol administration in humans lowers plasma nerve growth factor level: evidence that sedation induces opposite effects to arousal. Pharmacopsychiatry 36: 65-68
5. Aloe L, Iannitelli A, Angelucci F, Bersani G, Fiore M (2000) Studies in animal models and humans suggesting a role of nerve growth factor in schizophrenia-like disorders. Behav Pharmacol 11: 235-242
6. American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders, 4th edn. American Psychiatric Press, Washington, DC
7. Andreasson S, Allebeck P, Engstrom A, Rydberg U (1987) Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet 2: 1483-1486
8. Bersani G, Iannitelli A, Maselli P, Pancheri P, Aloe L, Angelucci F, Alleva E (1999) Low nerve growth factor plasma levels in schizophrenic patients: a preliminary study. Schizophrenia Res 37: 201-203
9. Bonnin A, de Miguel R, Castro JG, Ramos J A, Fernandez-Ruiz J J (1996) Effects of perinatal exposure to delta 9-tetrahydrocannabinol on the fetal and early postnatal development of tyrosine hydroxylase-containing neurons in rat brain. J Mol Neurosci 7: 291-308
10. Chaperon F, Thiebot M H (1999) Behavioural effects of cannabinoid agents in animals. Crit Rev Neurobiol 13: 243-281
11. Coffey C, Carlin J B, Degenhardt L, Lynskey M, Sanci L, Patten G C (2002) Cannabis dependence in young adults: an Australian population study. Addiction 97: 187-194
12. Conway K P, Swendsen J D, Rounsaville B J, Merikangas K R (2002) Personality, drug of choice, and comorbid psychopathology among substance abusers. Drug Alcohol Depend 65: 225-234
13. Croxford J L (2003) Therapeutic potential of cannabinoids in CNS disease. CNS Drugs 17: 179-202
14. Drogen- und Suchtbericht des Landes Berlin (1997) Hrsg, Landesdrogenbeauftragte von Berlin
15. Ehrenreich H, Rinn T, Kunert H J, Moeller M R, Poser W, Schilling L, Gigerenzer G, Hoehe M R (1999) Specific attentional dysfunction in adults following early start of cannabis use. Psychopharmacology (Berl) 142: 295-301
16. Elwan O, Hassan A A, Abdel Naseer M, Elwan F, Deif R, El Serafy O, El Banhawy E, El Fatatry M (1997) Brain aging in a sample of normal Egyptians cognition, education, addiction and smoking. J Neurol Sci 148: 79-86
17. Ganguli R, Brar J S, Rabin B S (1994) Immune abnormalities in schizophrenia: evidence for the autoimmune hypothesis. Harv Rev Psychiatry 2: 70-83
18. Häfner H, Behrens S, de Vry J, Gattaz W F (1991) Schizophrenia: gender and age. Why is the onset of schizophrenia later in women? Biol Psychiatry 1: 431-433
19. Harrison P J (1999) The neuropathology of schizophrenia: a critical review of the data and their interpretation. Brain 122: 593-624
20. Hellweg R, Hock C, Hartung H D (1989) An improved and highly sensitive enzyme immunoassay for nerve growth factor. J Meth Cell Mol Biol 1: 43-49
21. Hellweg R, von Richthofen S, Anders D, Baethge C, Röpke S, Hartung H D, Gericke C (1998) The time course of nerve growth factor content in different neuropsychiatric diseases - a unifying hypothesis. J Neural Transm 105: 871-903
22. Hernandez M L, Garcia-Gil L, Berrendero F, Ramos J A, Fernandez-Ruiz J J (1997) Delta 9-tetrahydrocannabinol increases activity of tyrosine hydroxylase in cultured fetal mesencephalic neurons. J Mol Neurosci 8: 83-91
23. Hörtnagl H, Hellweg R (1997) Insights into the role of the cholinergic component of the septohippocampal pathway: what have we learnt from experimental lesion studies? Brain Res Bull 43: 245-255
24. Hollister L E (1986) Health aspects of cannabis. Pharmacol Rev 38: 1-20
25. Jentsch J D, Verrico C D, Le D, Roth R H (1998) Repeated exposure to delta 9-tetrahydrocannabinol reduces prefrontal cortical dopamine metabolism in the rat. Neurosci Lett 246: 169-172
26. Jockers-Scherübl M C, Zouboulis C C, Boegner F, Hellweg R (1996) Is nerve growth factor a serum marker for neurological and psychiatric complications in Behcet's disease? Lancet 347: 982
27. Jockers-Scherübl M C, Kuhn S, Matthies U, Hellweg R (2000) Nerve growth factor (NGF) in schizophrenics with and without cannabis abuse. Schizophren Res 41: 251
28. Jones P, Cannon M (1998) The new epidemiology of schizophrenia. Psychiatr Clin North Am 21: 1-25
29. Kish S J, Kalasinsky K S, Furukawa Y, Guttman M, Ang L, Li L, Adams V, Reiber G, Anthony R A, Anderson W, Smialek J, DiStefano L (1999) Brain choline acetyltransferase activity in chronic, human users of cocaine, methamphetamine, and heroin. Mol Psychiatry 4: 26-32
30. Kornhuber J, Schultz A, Wiltfang J, Meineke I, Gleiter C H, Zochling R, Boissl K W, Leblhuber F, Riederer P (1999) Persistence of haloperidol in human brain tissue. Am J Psychiatry 156: 885-890
31. Korsching S, Auburger G, Heumann R, Scott J, Thoenen H (1985) Levels of nerve growth factor and its mRNA in the central nervous system of the rat correlate with cholinergic innervation. EMBO J 4: 1389-1393
32. Lang U E, Piche E, Juenger M, Schlattmann P, Jockers-Scherübl M, Hellweg R (2002) Nerve growth factor serum levels in patients with acute forms of atopic dermatitis. Dermatol Psychosom 3: 30-33
33. Levi-Montalcini R, Skaper S D, Dal Toso R, Petrelli L, Leon A (1996) Nerve growth factor: from neurotrophin to neurokine. Trends Neurosci 19: 514-520
34. Lewin G R, Barde Y A (1996) Physiology of the neurotrophins. Annu Rev Neurosci 19: 289-317
35. Lin A, Kenis G, Bignotti S, Tura G J, De Jong R, Bosmans E, Pioli R, Altamura C, Scharpe S, Maes M (1998) The inflammatory response system in treatment resistant schizophrenia: increased serum interleukin-6. Schizophr Res 32. 9-15
36. Lindvall O, Kokaia Z, Bengzon J, Elmer E, Kokaia M (1994) Neurotrophins and brain insults. Trends Neurosci 17: 490-96
37. Linszen D H, Dingemans P M, Lenior M E (1994) Cannabis abuse and the course of recent-onset schizophrenic disorders. Arch Gen Psychiatry 51: 273-279
38. Martin B R (1995) Marijuana. In Bloom F E, Kupfer D J (eds), Psychopharmacology: the fourth generation of progress. Raven Press, New York
39. Missale C, Boroni F, Sigala S, Buriani A, Fabris M, Leon A, Dal Tosso R, Spano P (1996) Nerve growth factor in the anterior pituitary: localization in mammotroph cells and cosecretion with prolactin by a dopamine-regulated mechanism. Proc Natl Acad Sci USA 93: 4240-4245
40. Navarro M, de Miguel R, Rodriguez de Fonseca F, Ramos J A, Fernandez-Ruiz J J (1996) Perinatal cannabinoid exposure modifies the sociosexual approach behaviour and the mesolimbic dopaminergic activity of adult male rats. Behav Brain Res 75: 91-98
41. Obrocki J, Buchert R, Väterlein O, Thomasius R, Beyer W (1999) Ecstasy - long-term effects on the human central nervous system revealed by positron emission tomography. Br J Psychiatry 175: 186-188
42. Patton G C, Coffey C, Carlin J B, Degenhardt L, Lynskey M, Hall W (2002) Cannabis use and mental health in young people: cohort study. BMJ 325: 1195-1198
43. Perkonnig A, Lieb R, Hofler M, Schuster P, Sonntag H, Wittchen H U (1999) Patterns of cannabis use, abuse and dependence over time: incidence, progression and stability in a sample of 1228 adolescents. Addiction 94: 1663-1678
44. Raedler T J, Knable M B, Weinberger D R (1998) Schizophrenia as a developmental disorder of the cerebral cortex. Curr Opin Neurobiol 8: 157-161
45. Ricaurte G A, McCann D U (1992) Neurotoxic amphetamine analogues: effects in monkeys and implications for humans. Ann NY Acad Sci 648: 371-382
46. Robson P (2001) Therapeutic aspects of cannabis and cannabinoids. Br J Psychiatry 178: 107-115
47. Ruberti F, Capsoni S, Comparini A, Di Daniel E, Franzot J, Gonfloni S, Rossi G, Berardi N, Cattaneo A (2000) Phenotypic knockout of nerve growth factor in adult transgenic mice reveals severe deficits in basal forebrain cholinergic neurons, cell death in the spleen, and skeletal muscle dystrophy. J Neurosci 20: 2589-2601
48. Schaub R T, Anders D, Golz G, Göhringer K, Hellweg R (2002) Serum nerve growth factor concentration and its role in the preclinical stage of dementia. Am J Psychiatry 159: 1227-1229
49. Schydlower M (2002)Adolescent substance use and abuse: current issues. Tex Med 98: 31-35
50. Siegel G J, Chauhan N B (2000) Neurotrophic factors in Alzheimer's and Parkinson's disease brain. Brain Res Rev 33: 199-227
51. Solowij N, Stephens R S, Roffman R A, Babor T, Kadden R, Miller M, Christiansen K, McRee B, Vendetti J, for the Marijuana Treatment Project Research Group (2002) Cognitive functioning of long-term heavy cannabis users seeking treatment. JAMA 287: 1123-1131
52. Tanda G, Pontieri F E, Di Chiara G (1997) Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mul opioid receptor mechanism. Science 276: 2048-2050
53. Toyooka K, Asama K, Watanabe Y, Muratake T, Takahashi M, Someya T, Nawa H (2002) Decreased levels of brain-derived neurotrophic factor in serum of chronic schizophrenic patients. Psychiatry Res 110: 249-257
54. Van der Zee C E, Lourenssen S, Stanisz J, Diamond J (1995) NGF deprivation of adult rat brain results in cholinergic hypofunction and selective impairments in spatial learning. Eur J Neurosci 7: 160-168
55. Weinberger D R (1999) Cell biology of the hippocampal formation in schizophrenia. Biol Psychiatry 45: 395-402